for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AxoGen Inc

AXGN.OQ

Latest Trade

9.57USD

Change

0.00(0.00%)

Volume

103,237

Today's Range

9.20

 - 

9.64

52 Week Range

9.11

 - 

23.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.57
Open
9.22
Volume
103,237
3M AVG Volume
4.22
Today's High
9.64
Today's Low
9.20
52 Week High
23.92
52 Week Low
9.11
Shares Out (MIL)
41.56
Market Cap (MIL)
383.62
Forward P/E
-23.08
Dividend (Yield %)
--

Next Event

Q4 2021 AxoGen Inc Earnings Release

Latest Developments

More

Axogen Reports 2021 Q3 Financial Results

AxoGen Posts Q2 Loss Per Share Of $0.19

Axogen Says It Will Suspend Market Availability Of Avive Soft Tissue Membrane Effective June 1, 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AxoGen Inc

Axogen, Inc. is focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers Axotouch Two-Point Discriminator, used to measure the innervation density of any surface area of the skin. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which can range from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its portfolio of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Industry

Medical Equipment & Supplies

Contact Info

13631 Progress Blvd Ste 400

ALACHUA, FL

32615-9409

United States

+1.386.4626817

https://www.axogeninc.com/

Executive Leadership

Karen L. Zaderej

Chairman of the Board, President, Chief Executive Officer

Peter J. Mariani

Chief Financial Officer

Maria D. Martinez

Chief Human Resource Officer

Brad Ottinger

Chief Compliance Officer, General Counsel

Mike Donovan

Vice President - Operations

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.340

2019

-0.420

2020

-0.380

2021(E)

-0.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.99
Price To Book (MRQ)
3.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.12
LT Debt To Equity (MRQ)
40.11
Return on Investment (TTM)
-15.32
Return on Equity (TTM)
-13.72

Latest News

Latest News

BRIEF-Axogen Announces New Seven-Year Financing Agreement With Oberland Capital

* AXOGEN ANNOUNCES NEW SEVEN-YEAR FINANCING AGREEMENT WITH OBERLAND CAPITAL AND PROVIDES PRELIMINARY SECOND QUARTER REVENUE ESTIMATE

BRIEF-Axogen Appoints Brad Ottinger As General Counsel, Chief Compliance Officer

* AXOGEN, INC. ANNOUNCES PLANNED RETIREMENT OF GREG FREITAG AND APPOINTS BRAD OTTINGER AS GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER Source text for Eikon: Further company coverage:

BRIEF-Axogen Inc Sees Q1 Revenue About $24.3 Mln

* AXOGEN, INC. REPORTS PRELIMINARY REVENUE FOR THE FIRST QUARTER 2020, PROVIDES BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC, AND ANNOUNCES DISMISSAL OF CLASS ACTION LAWSUIT

BRIEF-Axogen Says Coronavirus To Negatively Impact Co's Financial Results

* AXOGEN INC -LIMITATIONS CAUSED BY EVOLVING COVID-19 PANDEMIC & MACROECONOMIC ENVIRONMENT, WILL NEGATIVELY IMPACT CO'S FINANCIAL RESULTS

BRIEF-Axogen Posts Quarterly Adjusted Loss Per Share Of $0.10

* AXOGEN, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up